Adult
Efferon LPS
A CE-marked, single-use multimodal extracorporeal blood purification device used at the acute settings to treat sepsis, septic shock, cytokine storm, and endotoxemia.
Device Features
- Selective adsorption of lipopolysaccharides
- Non-selective adsorption of cytokines, myoglobin, cellular debris, endogenous and exogenous toxic substances
- Ready to use, sterile and pyrogen-free
- Low flow resistance, uniform flow
- Tough polycarbonate column
- Simple and reliable design eliminates connection errors
- Standard dialysis connectors for perfusion machines
- Firm and stable polymer does not crumble or dust
- No organic impurity emissions
- High hemocompatibility, low thrombogenic activity
Specifications
- Polymeric adsorbent
- Macroporous hypercrosslinked styrene-divinylbenzene copolymer with immobilized LPS-selective ligand, suspension in saline
- Total internal volume
- 210 ml
- Adsorbent volume
- 190 ml
- Blood filling volume
- 50–100 ml
- Recommended blood flow rate through the device
- 100–300 ml/min
- Construction
- Symmetrical polycarbonate cylinder with two end filters, O-rings and side covers with screw caps
- Weight
- 350 g
- Diameter × length
- 6 × 22 cm
- Individual packing
- PE / PA bag
- Sterilization
- radiation sterilization
Intended use
The device is intended for extracorporeal blood purification via an extracorporeal circuit. It can be performed as isolated hemoadsorption mode or in combination with RRT, ECMO and CPB. Inflammatory mediators and endotoxin are removed from patients' circulation. Timely administration improves vital functions and hinders progression of multiple organ failure in sepsis patients.
Clinical Data
In the multicenter randomized LASSO trial, treatment with Efferon LPS was associated with faster resolution of septic shock and improved hemodynamic stability, including a rapid increase in mean arterial pressure (MAP) and reduced vasopressor requirements. Patients treated with Efferon LPS also demonstrated shorter shock duration, earlier weaning from mechanical ventilation, reduced ICU and hospital length of stay, and improved early survival compared to standard therapy alone.
Instructions for use
Full instruction for use covering preparation, priming, perfusion and disposal protocols.
Download PDFMore products
Multimodal hemoadsorption
Clinically validated multimodal hemoadsorption technology that simultaneously removes bacterial endotoxin and excessive cytokines directly from the bloodstream, addressing key molecular drivers of sepsis and acute inflammation
